The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 04, 2021
Filed:
Apr. 05, 2018
Celgene Corporation, Summit, NJ (US);
Matthew William Burnell Trotter, Seville, ES;
Patrick Hagner, Sparta, NJ (US);
Courtney G. Havens, Morristown, NJ (US);
Rajesh Chopra, Summit, NJ (US);
Anita Gandhi, Bernardsville, NJ (US);
Anke Klippel, Westfield, NJ (US);
Maria Yinglin Wang, San Diego, CA (US);
Mike Breider, Cardiff-by-the-Sea, CA (US);
Suzana Sturlini Couto, La Jolla, CA (US);
Yan Ren, San Diego, CA (US);
Paul Hollenbach, Castro Valley, CA (US);
Kyle Macbeth, San Francisco, CA (US);
CELGENE CORPORATION, Summit, NJ (US);
Abstract
Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.